Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024. All figures are in AU$...

Autohome Inc. Announces Change in Controlling Shareholder and Management Change

Autohome Inc. Announces Change in Controlling Shareholder and Management Change

BEIJING, Feb. 20, 2025 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that the Company has been informed by Yun Chen Capital...

Autohome Inc. Announces 2024 Q4 and Annual Earnings: Growth in New Retail Business and AI-Powered Product Upgrades

Autohome Inc. Announces 2024 Q4 and Annual Earnings: Growth in New Retail Business and AI-Powered Product Upgrades

HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced its fourth quarter and annual financial results for...

Autohome Inc. Announces Unaudited Fourth Quarter and Full Year 2024 Financial Results

Autohome Inc. Announces Unaudited Fourth Quarter and Full Year 2024 Financial Results

BEIJING, Feb. 20, 2025 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced its unaudited financial results for the three months and...

NetEase Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

NetEase Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

HANGZHOU, China, Feb. 20, 2025 /PRNewswire/ -- NetEase, Inc. (NASDAQ: NTES and HKEX: 9999, "NetEase" or the "Company"), a leading internet and game services provider, today announced its unaudited financial results for the fourth quarter and fiscal...

Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research

Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research

CAMBRIDGE, Mass., Feb. 20, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with the University of Alabama at Birmingham (UAB) to...

Eason Technology Limited Announces Acquisition of Blockchain Technology Company

Eason Technology Limited Announces Acquisition of Blockchain Technology Company

HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason" or the "Company") (NYSE American: DXF), a company engaged in real estate operation management and investment, and digital technology security business, today announced that...

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 19TH + NIKE ANNOUNCES COLLABORATION WITH SKIMS

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 19TH + NIKE ANNOUNCES COLLABORATION WITH SKIMS

NEW YORK, Feb. 19, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE...

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) c ohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg , and 40 mg). - ASC30 oral once-daily tablet also...

UTILITY ANNOUNCES PARKER MEEKS AS NEW CHIEF EXECUTIVE OFFICER

UTILITY ANNOUNCES PARKER MEEKS AS NEW CHIEF EXECUTIVE OFFICER

Meeks' initial focus includes driving active commercialization phase for Utility's leading clean hydrogen production technology, profitably transitioning heavy-industry across a strong global pipeline HOUSTON, Feb. 18, 2025 /PRNewswire/ -- Utility,...

  • 1
  • ...
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • ...
  • 152
  • menu
    menu